Vitro Diagnostics Company Announces Partnership To Expand DKD Medicine Solutions
Renalytix and Steno Diabetes Center Announce Precision Medicine Collaboration: Expanding KidneyIntelX Beyond the US.
Renalytix plc, a leading artificial intelligence-enabled in vitro diagnostics company, has announced an exciting new collaboration with the Steno Diabetes Center in Copenhagen. This partnership aims to advance precision medicine solutions for patients suffering from diabetes and chronic kidney disease (DKD). This announcement is particularly noteworthy as it indicates the first expansion of Renalytix's KidneyIntelX platform beyond the United States, marking a step in the global fight against chronic kidney disease. $Renalytix (RNLX.US)$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
